Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - nci_ncicdr0000062910-nci-header
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Prostate Cancer Treatment
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview for Prostate Cancer
Local treatment modalities are associated with prolonged disease-free survival for many patients with localized prostate cancer but are rarely curative in patients with locally extensive tumors. Because of clinical understaging using current diagnostic techniques, even when the cancer appears clinically localized to the prostate gland, some patients develop disseminated tumors after local therapy with surgery or radiation. Metastatic prostate cancer is currently not curable.Treatment options for each stage of prostate cancer are presented in Table 9.Table 9. Treatment Options by Stage for Prostate CancerStage (TNM Staging Criteria)Standard Treatment OptionsTURP = transurethral resection of the prostate.Stage I Prostate CancerWatchful waiting or active surveillanceRadical prostatectomyExternal-beam radiation therapy (EBRT)Interstitial implantation of radioisotopesStage II Prostate CancerWatchful waiting or active
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage II Prostate Cancer Treatment
OverviewStage II prostate cancer is defined by the American Joint Committee on Cancer's TNM classification system:Stage IIAT1a–c, N0, M0, prostate-specific antigen (PSA) <20 ng/ml, Gleason 7.T1a–c, N0, M0, PSA ≥10 <20 ng/ml, Gleason ≤6.T2a, N0, M0, PSA ≥10 <20 ng/ml, Gleason ≤6.T2a, N0, M0, PSA <20 ng/ml, Gleason 7.T2b, N0, M0, PSA <20 ng/ml, Gleason ≤7.T2b, N0, M0, PSA X, Gleason X.Stage IIBT2c, N0, M0, any PSA, any Gleason.T1–2, N0, M0, PSA ≥20 ng/ml, any Gleason.T1–2, N0, M0, any PSA, Gleason ≥8.Radical prostatectomy, external-beam radiation therapy (EBRT), and interstitial implantation of radioisotopes are each employed in the treatment of stage II prostate cancer with apparently similar therapeutic effects. Radical prostatectomy and radiation therapy yield apparently similar survival rates with as many as 10 years of follow-up. For well-selected patients, radical prostatectomy
Prostate Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Prostate Cancer
For more information from the National Cancer Institute about prostate cancer,see the following: Prostate Cancer What You Need to Know About™ Prostate Cancer Prostate Cancer Prevention Prostate Cancer Screening Treatment Choices for Men with Early-Stage Prostate Cancer Early Prostate Cancer: Questions and Answers The Prostate-Specific Antigen (PSA) Test: Questions and Answers Cryosurgery in ...
Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Prostate Cancer
Carcinoma of the prostate is predominantly a tumor of older men: the median age at diagnosis is 72 years. Prostate cancer may be cured when localized, and it frequently responds to treatment when widespread. The rate of tumor growth varies from very slow to moderately rapid, and some patients may have prolonged survival even after the cancer has metastasized to distant sites, such as bone. The 5-year relative survival rate for men diagnosed in the United States from 2001 to 2007 with local or regional disease was 100%, and the rate for distant disease was 28.7%; a 99% survival rate was observed for all stages combined.[SEER Stat Fact Sheets: Prostate] The approach to treatment is influenced by age and coexisting medical problems. Side effects of various forms of treatment should be considered in selecting appropriate management.Many patients—especially those with localized tumors—may die of other illnesses without ever having suffered disability from the cancer, even
Prostate Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Significance
Incidence and Mortality Carcinoma of the prostate is the most common tumor in men in the United States,with 234,460 new cases and 27,350 deaths expected in 2006.[ 1 ] A wide range of estimates of the impact of the disease are notable. The disease is histologically evident in as many as 34% of men in their fifth decade and in up to 70% of men aged 80 years and older.[ 2,3 ] Prostate cancer ...
Prostate Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary,please send them to Cancer.gov through the Web site’s Contact Form. We can respond only to email messages written in English. ...
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Questions and Answers About Zyflamend
What is Zyflamend?Zyflamend is a dietary supplement that contains 10 different herbs. Zyflamend contains extracts of rosemary, turmeric, ginger, holy basil, green tea, hu zhang (Polygonum cuspidatum, a source of resveratrol), Chinese goldthread, barberry, oregano, and Baikal skullcap.The extracts found in Zyflamend have anti-inflammatory activity and possible anticancer benefits. There is limited evidence about how Zyflamend may act against tumor growth. Zyflamend has been shown to interfere with the activity of COX-1 and COX-2 enzymes, which are involved in the development of inflammation and possibly cancer. Zyflamend may also act against the NF-kappa B and lipoxygenase (LOX) families of proteins that stimulate tumor growth. How is Zyflamend administered or consumed?Zyflamend is taken as a dietary supplement in capsule form. Have any preclinical (laboratory or animal) studies been conducted using Zyflamend?Laboratory and animal research has recently been done to study the effects of
Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Questions to Ask Your Health Care Provider About CAM
When considering complementary and alternative therapies, patients should ask their health care provider the following questions: What side effects can be expected?What are the risks associated with this therapy?Do the known benefits outweigh the risks?What benefits can be expected from this therapy?Will the therapy interfere with conventional treatment?Is this therapy part of a clinical trial?If so, who is sponsoring the trial?Will the therapy be covered by health insurance?
Prostate Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Prostate Cancer
Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. The prostate is a gland in the male reproductive system located just below the bladder (the organ that collects and empties urine) and in front of the rectum (the lower part of the intestine). It is about the size of a walnut and surrounds part of the urethra (the tube that empties urine from the